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Abstract
Background: Competing molecular classification systems have been proposed to complement the TNM staging
system for a better prediction of survival in colorectal cancer (CRC). However, validation studies are so far lacking.
The aim of this study was to validate and extend previously published molecular classifications of CRC in a large
independent cohort of CRC patients.
Methods: CRC patients were recruited into a population-based cohort study (DACHS). Molecular subtypes were
categorized based on three previously published classifications. Cox-proportional hazard models, based on the
same set of patients and using the same confounders as reported by the original studies, were used to determine
overall, cancer-specific, or relapse-free survival for each subtype. Hazard ratios and confidence intervals, as well as
Kaplan-Meier plots were compared to those reported by the original studies.
Results: We observed similar patterns of worse survival for the microsatellite stable (MSS)/BRAF-mutated and
MSS/KRAS-mutated subtypes in our validation analyses, which were included in two of the validated
classifications. Of the two MSI subtypes, one defined by additional presence of CIMP-high and BRAF-mutation
and the other by tumors negative for CIMP, BRAF and KRAS-mutations, we could not confirm associations
with better prognosis as suggested by one of the classifications. For two of the published classifications, we
were able to provide results for additional subgroups not included in the original studies (men, other disease
stages, other locations).
Conclusions: External validation of three previously proposed classifications confirmed findings of worse
survival for CRC patients with MSS subtypes and BRAF or KRAS mutations. Regarding MSI subtypes, other
patient characteristics such as stage of the tumor, may influence the potential survival benefit. Further
integration of methylation, genetic, and immunological information is needed to develop and validate a
comprehensive classification that will have relevance for use in clinical practice.
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Background
Colorectal cancer (CRC) is a leading cause of cancer
incidence and mortality worldwide [1, 2]. Patient sur-
vival is generally well predicted according to the
TNM stage; however, there is still stage independent
variability due to the molecular heterogeneity of the
tumor [3]. Molecular characteristics of the tumor that
also affect patient survival, such as MSI, BRAF and
KRAS, have only recently been included in the 8th
edition of the UICC recommendations as additional
indicators for clinical practice guidance.
A deficiency in the MMR system, represented by
the microsatellite instability (MSI-H) phenotype, can
be found in approximately 15% of CRC cases, and is
associated with both sporadic (~ 12%) and hereditary
(~ 3%) cancers. Patients with the MSI-high phenotype
seem to have better survival than patients with micro-
satellite stable (MSS) tumors [4, 5]. The MSI status is
closely associated with other characteristics of the
tumor, such as BRAF mutations, early stage, proximal
location, and higher degree of immune infiltration.
Some clinical trials focusing on stage III patients re-
ceiving chemotherapy have reported conflicting results
regarding the prognosis of MSI-high patients [6–8],
which could be explained by the varying tumor char-
acteristics. Mutations in BRAF V600E and KRAS exon 2
were also associated with worse patient prognosis in previ-
ous studies; however, these associations seem to be re-
stricted to MSS tumors [9, 10]. In combination with the
TNM stage information, KRAS mutations and the MSI sta-
tus of the tumor are used in clinical practice to determine
treatment options [11, 12].
According to UICC recommendations, before a modi-
fied staging system can be endorsed for use in clinical
practice, a classification must be validated in various exter-
nal cohorts using different patient populations in several
settings [13]. In a previous systematic review, multiple
studies that proposed molecular subtype classifications of
CRC (including markers such as MSI, BRAF and KRAS)
and determining their associations with patient survival
were identified [14]. No classification found significant as-
sociations for all proposed subtypes and only two per-
formed external validation of their results [15, 16]. Given
the importance of external validation of such classifica-
tions, the aim of this study was to validate CRC molecular
subtype classifications previously published in the litera-
ture and extend their application to additional patient
subgroups not previously investigated, using an independ-
ent cohort of patients from a population-based study.
Methods
Study population and design
The DACHS study is a population-based case-control
study conducted in the Rhine-Neckar region in southern
Germany, in which incident CRC cases are followed-up
as a cohort. Details of the study design have been re-
ported previously [17]. Briefly, patients over 30 years of
age, with a histologically confirmed diagnosis of CRC,
and able to participate in an interview in German, were
recruited between 2003 and 2010 from 22 hospitals in
the region. Patients with available tumor tissue samples,
molecular characterization on MSI, BRAF, KRAS and
CIMP, and follow-up were included in this analysis.
Baseline characteristics, and medical and family history
of CRC were collected by trained interviewers at the time
of diagnosis using a standardized questionnaire. Tumor
characteristics and stage of disease (6th edition of the
TNM staging manual) were obtained from medical re-
cords and pathology reports. Follow-up assessment at 3
and 5 years after diagnosis included information on the
type of treatment, comorbidities, cancer recurrence, and
vital status. Vital status and date of death were obtained
from population registries, and determination of cause of
death was based on death certificates obtained from the
pertinent health authorities.
Molecular marker determination
Tumor tissue analyses were performed on formalin
fixed, paraffin embedded (FFPE) samples. As previously
described, MSI status was determined using a mononu-
cleotide marker panel (BAT25, BAT26 and CAT25) [18].
BRAF V600E was determined independently by two ex-
perienced pathologists (HBl, MK) using IHC analyses in
tissue microarray blocks (52%) and by mutational ana-
lysis (48%) using Sanger sequencing (exon 15). No sig-
nificant differences were observed in the proportion of
aberrant cases identified by the two techniques. KRAS
mutations were determined using DNA samples by the
single stranded conformational polymorphism technique
(48%) or by Sanger sequencing (52%) (exon 2). CIMP
status was defined using a five marker methylation panel
(MLH1, MINT1, MINT2, MINT31 and MGMT) and
classified according to the number of hyper-methylated
loci: CIMP negative (none), CIMP-low (1 or 2 loci), or
CIMP-high (3 or more loci).
Studies for comparison
Studies with proposed molecular subtypes of colorectal
or colon cancers that provided an estimation of the asso-
ciation with survival for each subtype were identified in
a previous systematic review [14] and used as a base to
perform this external validation analysis. Studies were
included in the systematic review if they suggested a
classification system based on at least three markers and
reported results for survival by each subtype. In this val-
idation analysis we were able to include classifications of
CRC based on the molecular subtypes previously sug-
gested by Jass [19], including MSI and CIMP status, and
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mutation status of BRAF and KRAS genes [16, 20, 21].
Table 1 presents a summary of the population and study
characteristics of the studies included in this analysis.
Validation and statistical analysis
Demographic and clinico-pathological characteristics were
analyzed for the entire study population using descriptive
statistics. Patients were categorized into the same subtypes
proposed by the three studies. Cox-proportional hazards
regression models were used to calculate cancer-specific
(CSS), relapse-free (RFS), or overall survival (OS) for each
subtype. CSS was defined as time from diagnosis until
death from CRC, RFS until reappearance of disease, me-
tastases or death from CRC, and OS until death from any
cause. All models were adjusted using the same set of var-
iables reported by the original studies. Classifications that
were developed only among women, or only in stage III
colon cancer patients were validated in both the selected
sub-population and the entire patient cohort, to investi-
gate whether the classification would yield similar results
in an unselected patient cohort.
For the validation of the proposed classifications, the
hazard ratios reported by the original studies were com-
pared with those obtained in the DACHS cohort after
creating subtypes equal to those proposed by the original
studies. As suggested by Royston and Altman [22],
Kaplan-Meier plots were created to evaluate the discrim-
ination between subtypes and to allow a visual compari-
son of discrimination with the originally published plots.
Additionally, Uno’s c-statistic was calculated for each of
the models [23]. This method provides a measure of dis-
crimination that accounts for time-to-event data and
censoring in survival analyses [24]. All statistical analyses
were performed in SAS version 9.4 (SAS Institute Inc.,
Cary, NC, USA).
Results
DACHS population characteristics
Among 1915 cases with complete tumor marker data,
patients were classified according to the TNM system as
stage I in 355 (19%), stage II in 644 (34%), stage III in
652 (34%), and stage IV in 264 (14%) cases. The MSI
and CIMP status, and mutations in BRAF were signifi-
cantly associated with age, sex, location and stage of dis-
ease in descriptive analyses (Table 2). During a median
follow-up of 5.3 years, 548 (29%) patients experienced
disease recurrence, and 624 (33%) patients died, 414
(66%) of whom from CRC. CRC-specific deaths occurred
in 20 (9%) MSI-high cases, 44 (28%) BRAF mutated
cases, 144 (23%) KRAS mutated cases, and 66 (19%)
CIMP-high cases.
External validation results
Table 3 presents the molecular classification, original re-
sults, and validation results obtained with the DACHS co-
hort. In general, the distribution of patients from the
DACHS study within each classification was similar to the
one reported by the original studies. Larger differences be-
tween the original studies and our study were observed
for the ‘Traditional’ (45.9% vs 56.8%) and ‘Alternate’
Table 1 Characteristics of studies for validation
Studies with proposed classifications to be validated Validation set
Samadder et al.
[20] 2013
Phipps et al. [21] 2015 Sinicrope et al. [16] 2015
Study Iowa Women’s
Health Study
Seattle Colon Cancer Family Registry Phase III randomized trial NCCTG
N0147
DACHS study
Study
design
Cohort Population-based cohort Cohort from clinical trial Population-based cohort
N 370 1189 2720 1915
Country US US US Germany
Population Women aged 55–
69 resident in
Iowa
Persons aged 20–74 resident in Washington
state and women 50–74 in postmenopausal
study
Patients aged 19–86 with resected
stage III colon carcinomas in Alabama
region
Patients aged 30–96
resident in Rhine-Neckar
region
Cancer Colorectal Colorectal Colon Colorectal
Stage I - IV I - IV III I - IV
Recruitment
time
1986–2002 1998–2007 2004–2012 2003–2010
Treatment Any Any FOLFOX or FOLFOX+cetuximab Any
Outcomes CSS, OS CSS, OS DFS CSS, RFS, OS
Median
follow-up
NR NR 4.9 years 5.3 years
DACHS Darmkrebs, Chancen der Verhütung durch Screening, US United States, CSS cancer-specific survival, DFS disease-free survival, OS overall survival, NR
not reported
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(38.4% vs 32.0%) subtypes proposed by Samadder et al.
[20], and the ‘Type 4’ subtype proposed by Phipps et al.
[21] (4.6% vs 1.7%). Due to the selective recruitment of
stage III patients in the study by Sinicrope et al. [16],
numbers of patients were lower for all subtypes in the
DACHS study.
In a study restricted to female CRC patients, Samadder
et al. [20] proposed three molecular subtypes and two
additional ‘unassigned’ subgroups. The two unassigned
groups were not clearly defined, and therefore not in-
cluded in this validation. Both BRAF and KRAS mutated
subtypes showed worse CSS compared to the all-negative
baseline, however none of the associations were statisti-
cally significant. In the DACHS cohort, the magnitudes
and directions of the measures of effect were similar in all
subtypes for CSS and OS, but no significant associations
were observed either. The c-statistic for the CSS and OS
models was 0.828 and 0.780, respectively.
Phipps et al. [21] proposed five molecular subtypes
and found significantly worse CSS for the MSS subtypes
(types 2 and 3), and better CSS for the type 5 (MSI-high,
BRAF non-mutated, KRAS non-mutated, CIMP-
negative) subtype in comparison to the type 4 (MSS,
BRAF non-mutated, KRAS non-mutated, CIMP-
negative) subtype [21]. In the DACHS cohort, the
magnitude and direction of the effect for CSS and OS
were similar for the MSS subtypes (types 2 and 3). The
MSI-high subtypes were not significantly associated with
better survival (type 1: HR = 0.93 [0.5–1.8]; type 5: HR =
1.04 [0.4–2.5]), regardless of the BRAF or KRAS muta-
tional status. The c-statistic for the CSS and OS models
was 0.797 and 0.744, respectively.
Sinicrope et al. [16] described five molecular subtypes
in a cohort of stage III colon cancer patients recruited in
the N0147 clinical trial. Significantly worse CSS was ob-
served for both KRAS mutated and BRAF mutated MSS
subtypes, and no significant associations were found for
either of the MSI-high subtypes compared to the MSS
non-mutated subtype [16]. These findings were similar
in the DACHS cohort, where HRs for RFS showed worse
survival in the MSS groups and no significant associa-
tions in the MSI-high subtypes. The c-statistic for this
model was 0.723.
Extended analyses in patient subgroups not available
from the original studies
In exploratory analyses, the classifications were validated
using additional subgroups of DACHS patients (see
Table 3). Similar to the results in the main analysis, no
significant associations were found for the classification
Table 2 Descriptive characteristics of CRC patients according to molecular markers in the DACHS cohort
Variable
n (%)
Overall
n = 1915
MSS
n = 1698
(89%)
MSI
n = 217
(11%)
p-val BRAF wt
n = 1759
(92%)
BRAF mut
n = 156
(8%)
p-val KRAS wt
n = 1293
(68%)
KRAS mut
n = 622
(32%)
p-val CIMP-low
n = 1572
(82%)
CIMP-high
n = 343
(18%)
p-val
Age groups
< 65 629 (33) 566 (33) 63 (29) < 0.001 598 (34) 31 (20) < 0.001 437 (34) 192 (31) 0.425 551 (35) 78 (23) < 0.001
65–74 654 (34) 596 (35) 58 (27) 609 (35) 45 (29) 433 (33) 221 (36) 542 (35) 112 (33)
> 75 632 (33) 536 (32) 96 (44) 552 (31) 80 (51) 423 (33) 209 (34) 479 (31) 153 (45)
Sex
Female 808 (42) 690 (41) 118 (54) < 0.001 705 (40) 103 (66) < 0.001 547 (42) 261 (42) 0.887 625 (40) 183 (53) < 0.001
Male 1107 (58) 1008 (59) 99 (46) 1054 (60) 53 (34) 746 (58) 361 (58) 947 (60) 160 (47)
Location
Proximal colon 684 (36) 501 (30) 183 (85) < 0.001 555 (32) 129 (83) < 0.001 441 (35) 243 (40) 0.100 464 (30) 220 (64) < 0.001
Distal colon 497 (26) 476 (28) 21 (10) 483 (28) 14 (9) 344 (27) 153 (25) 441 (28) 56 (16)
Rectum 714 (38) 703 (42) 11 (5) 702 (40) 12 (8) 495 (39) 219 (36) 648 (42) 66 (19)
TNM stage
Stage I 355 (19) 321 (19) 34 (16) < 0.001 336 (19) 19 (12) 0.068 239 (19) 116 (19) 0.276 293 (19) 62 (18) 0.015
Stage II 644 (34) 525 (31) 119 (55) 580 (33) 64 (41) 453 (35) 191 (31) 504 (32) 140 (41)
Stage III 652 (34) 594 (35) 58 (27) 603 (34) 49 (31) 428 (33) 224 (36) 553 (35) 99 (29)
Stage IV 264 (14) 258 (15) 6 (3) 240 (14) 24 (15) 173 (13) 91 (15) 222 (14) 42 (12)
Chemotherapy
No 1045 (55) 893 (53) 152 (71) < 0.001 948 (54) 97 (63) 0.036 714 (56) 331 (53) 0.343 829 (53) 216 (63) < 0.001
Yes 857 (45) 794 (47) 63 (29) 800 (46) 57 (37) 568 (44) 289 (47) 731 (47) 126 (37)
MSS microsatellite stability, MSI microsatellite instability, BRAF wt BRAF wild type, BRAF mut BRAF mutated, KRAS wt KRAS wild-type, KRAS mut KRAS mutated
p-values from Chi-square or Fischer’s exact tests for the association of the two variables
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Table 3 Comparison of patient survival according to the identified classifications with external validation and additional subgroups
in the DACHS cohort
Original studies DACHS study
Author / Population Subtypes MSI BRAF KRAS CIMP n (%) HR (95%CI) HR (95%CI) n (%) HRa (95%CI) HRa (95%CI)
Samadder et al. [20] 2013 CSS OS CSS OS
Women, CRC Traditional – – – – 170 45.9 1 1 366 56.8 1 1
Serrated any + – + 58 15.7 1.56 (0.9–2.8) 1.23 (0.8–1.8) 72 11.2 1.37 (0.7–2.5) 1.04 (0.6–1.7)
Alternate – – + – 142 38.4 1.26 (0.7–2.4) 0.85 (0.6–1.3) 206 32 1.09 (0.7–1.6) 0.93 (0.7–1.3)
Total 370 644
Men Traditional – – – – Not reported in original study 598 65.5 1 1
Serrated any + – + 32 3.5 0.89 (0.3–2.5) 0.95 (0.4–2.0)
Alternate – – + – 283 31 1.21 (0.9–1.7) 1.24 (1.0–1.6)
Total 913
Both sexes Traditional – – – – Not reported in original study 964 61.9 1 1
Serrated any + – + 104 6.7 1.35 (0.8–2.2) 1.09 (0.7–1.6)
Alternate – – + – 489 31.4 1.15 (0.9–1.5) 1.08 (0.9–1.3)
Total 1557
Phipps et al. [21] 2015 CSS OS CSS OS
All stages, CRC Type 1 + + – + 100 8.4 0.54 (0.3–1.0) 1.05 (0.8–1.4) 77 4.8 0.93 (0.5–1.8) 0.83 (0.5–1.4)
Type 2 – + – + 55 4.6 1.84 (1.2–2.8) 1.40 (1.0–2.0) 27 1.7 1.83 (1.0–3.4) 1.55 (0.9–2.7)
Type 3 – – + – 353 29.7 1.25 (1.0–1.5) 1.23 (1.0–1.5) 489 30.4 1.18 (0.9–1.5) 1.13 (0.9–1.4)
Type 4 – – – – 631 53.1 1 1 964 60 1 1
Type 5 + – – – 50 4.2 0.42 (0.2–0.9) 0.74 (0.5–1.2) 50 3.1 1.04 (0.4–2.5) 1.51 (0.8–2.7)
Total 1189 1607
Sinicrope et al. [16] 2015 DFS b RFS
Stage III, colon Non BRAF/KRAS – – – 1331 48.9 1 137 49.1 1
Chemotherapy Mut KRAS – – + 945 34.7 1.48 (1.3–1.7) 102 36.6 1.39 (0.8–2.4)
N0147 trial Mut BRAF – + – 189 6.9 1.43 (1.1–1.8) 12 4.3 2.77 (1.1–7.2)
dMMR sporadic + + any MLH1 184 6.8 1.10 (0.8–1.5) 16 5.7 1.15 (0.4–3.2)
dMMR familial + – any 71 2.6 0.77 (0.5–1.3) 12 4.3 0.33 (0.1–2.6)
Total 2720 279
All stages, colon Non BRAF/KRAS – – – Not reported in original study 578 51.3 1
Mut KRAS – – + 361 32.1 1.31 (1.0–1.7)
Mut BRAF – + – 53 4.7 3.01 (1.9–4.7)
dMMR sporadic + + any MLH1 84 7.5 0.60 (0.3–1.1)
dMMR familial + – any 50 4.4 0.36 (0.1–1.0)
Total 1126
All stages, CRC Non BRAF/KRAS – – – Not reported in original study 1055 57.3 1
Mut KRAS – – + 578 31.4 1.18 (1.0–1.4)
Mut BRAF – + – 63 3.4 2.96 (2.0–4.4)
dMMR sporadic + + any MLH1 84 4.6 0.54 (0.3–1.0)
dMMR familial + – any 60 3.3 0.58 (0.3–1.2)
Total 1840
MSI microsatellite instability, dMMR deficient mismatch-repair, HR hazard ratio, CSS cancer-specific survival, OS overall survival, DFS disease-free
survival, RFS relapse-free survival
aAdjusted for what the original study adjusted for: Samadder et al.: Age, location, grade, stage, chemotherapy, radiotherapy. Phipps et al.: Age, sex,
stage, BMI, year of diagnosis, smoking. Sinicrope et al.: Age, sex, location, T stage, N stage, grade, lymph nodes examined, chemotherapy
bDFS: Defined as “time from date of randomization to first documented disease recurrence or death (due to all causes), whichever occurred first”.
Approximated here with RFS
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proposed by Samadder et al. [20] in analyses restricted
to men, although a tendency towards worse CSS and OS
in the MSS, KRAS mutated subgroup was observed.
This tendency was also observed for the subgroup ana-
lyses including both sexes, where HRs for CSS were
similar to those reported for women by the original
study. Stage-specific analyses for the classification pro-
posed by Phipps et al. [21] suggested a better survival
for MSI subtypes only in early stage patients (data not
shown). Extended analyses of Sinicrope’s [16] classifica-
tion including patients with all stages of colon and colo-
rectal cancers showed similar associations for the MSS
subtypes, and a borderline significant association of the
MSI subgroups with RFS.
Visual assessment of agreement with original studies
Figure 1 presents Kaplan-Meier plots for survival in the
DACHS cohort after categorizing patients according to
each of the proposed classifications. In the DACHS co-
hort (Fig. 1a), the Kaplan-Meier plot suggested a better
survival for the ‘Traditional’ pathway curve compared to
the one published by Samadder et al. [20] (Fig. 3B in the
original study). No differences were observed between
the ‘Alternate’ and ‘Serrated’ pathways. For the classifica-
tion proposed by Phipps et al. [21], a visual comparison
with the originally published Kaplan-Meier plots allowed
to infer good agreement with the type 2 subtype, which
corresponds to MSS, BRAF mutated, CIMP-positive tu-
mors. The other subtypes in this classification also
showed similar patterns of survival (Fig. 1b). However,
type 1 and type 5 (MSI-high subtypes) showed better
survival compared to the all-negative type 4 subtype in
the original study (Fig. 1 in the original study [21]). The
survival curves based on the classification by Sinicrope
et al. [16] (Fig. 1c), showed a worse pattern of RFS for
the MSS/BRAF mutated subtype. Even though the out-
comes were different (DFS and RFS) the patterns ob-
served in the Kaplan-Meier plots were similar to the
ones published by the authors in their own external val-
idation cohort (Fig. 3 in the original study [16]).
Discussion
In this external validation study of previously proposed
molecular subtype classifications for the prediction of
survival among CRC patients, we found that MSS can-
cers with BRAF or KRAS mutations generally conferred
a worse prognosis compared to tumors with no such
mutations. This finding was reported by two previous
studies, and we were able to validate their results both
in similar patient populations and additional subgroups
that were not included in the original studies. Overall,
all subtypes of the three proposed classifications showed
similar hazard ratios and levels of significance compared
to the ones reported by the original studies, except for
two MSI-high subtypes proposed by Phipps et al. [21]
for which we found no statistically significant associa-
tions of better survival.
In their study, Phipps et al. [21] described that patients
with MSI-high tumors with or without mutations in
BRAF or KRAS (types 1 and 5) had better survival than
those with MSS tumors. This reflects the findings of sev-
eral previous studies and meta-analyses where MSI-high
tumors had a better prognosis than MSS tumors [5]. In
our study, we found better survival for MSI-high tumors
compared to MSS tumors but no statistically significant
associations for the specific MSI subtypes (1 and 5). We
attribute this difference to the different way in which pa-
tients were distributed among the subtypes: i) the pro-
portion of stage I patients differs between the studies for
type 1 (47% in original study vs 13% in our study) and
type 5 (50% in original study vs 12% in our study); ii)
Phipps et al. [21] included a large proportion of patients
from a cohort of postmenopausal women and a second
recruitment round of patients diagnosed before 50 years
of age, whereas patients in our study reflect an older pa-
tient population with equal distribution of men and
women. These differences in population characteristics
might also be responsible for the observed survival in
the different subtypes.
None of the other studies included here provided
an estimate of survival for MSI-high subtypes with no
mutations in BRAF and KRAS. For example, Samad-
der et al. [20] provided only one subtype where MSI
status could be either negative or positive, and found
no significant associations with survival. Sinicrope et
al. [16] described two MSI-high subtypes without spe-
cifying the KRAS mutation status and found no sig-
nificant associations with DFS. Both subtypes were
also not associated with RFS in the validation ana-
lyses. This underlines the need to not only discrimin-
ate the MSI status of a tumor in any classification
[3], but to also include information on the BRAF and
KRAS mutational status. When conducting the ana-
lyses in different sets of patients (e.g. including all
stages and locations) the findings were similar.
Only one of the three studies (Sinicrope et al. [16])
had performed a validation analysis in an external pa-
tient population. No measures of effect were provided
for the validation cohort; however, the Kaplan-Meier
plot created in our validation analysis showed similar
patterns to the one provided in this study, especially for
the BRAF mutated subtype. Survival curves for the other
two studies also showed good agreement with the ones
generated in our analysis, particularly the MSS/BRAF
mutated subtype described by Phipps et al. [21].
Other CRC classifications have been published in re-
cent years [15, 25–27]. The consensus molecular subtype
(CMS) group included gene expression information in
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Fig. 1 Kaplan-Meier curves for each classification within DACHS patient cohort. A. Cancer-specific survival for the classification by Samadder et al.
[20] B. Cancer-specific survival for the classification by Phipps et al. [21] C. Relapse-free survival for the classification by Sinicrope et al. [16]
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their classification, and proposed four CRC subtypes for
which prediction of survival was only significant for one
[25]. The CMS classification system was not included in
the present validation analysis, because some informa-
tion required for the definition of the CMS subtypes was
not available from our study. The CMS1 subtype, how-
ever, which corresponds to the type 1 tumors reported
by Phipps et al. [21], was not significantly associated
with better survival, similar to our validation results for
type 1 tumors. Even though the proposed CMS subtypes
were derived from a complex methodology including in-
formation from several international studies, the infor-
mation required to classify a patient into the subtypes
may not be readily available in every clinical practice.
Other studies provided analyses stratifying for the
MSS status of the tumor, instead of including MSS as a
part of the classification and thus, were not included in
this validation analysis [9, 28]. These studies included
stage III colon cancer patients recruited in clinical trials
for chemotherapy treatment and found significant asso-
ciations only for MSS tumors with time to relapse and
survival after relapse [9, 28]. A recent analysis showed
that including molecular information as well as clinical
and pathological characteristics in survival models im-
proved their ability to predict overall survival in stage II
and III colon cancer patients [29]. This study represents
an important first step in optimizing the existing prog-
nostic classification system of CRC and will allow for
additional efforts to achieve an ideal classification. Add-
itionally, the Immunoscore showed independent prog-
nostic value for CRC survival after adjusting for the
TNM stage and shows promising ability to complement
the current system [30–32]. These results might be in-
fluenced by the close relation between immune infiltra-
tion and the MSI status of a tumor [33, 34], but could
add value to a prognostic classification that is to comple-
ment the traditional staging system. All these diverse
studies reflect the increasing international interest in the
development of a more comprehensive classification that
could help clinicians provide a more personalized treat-
ment to CRC patients [35].
Due to the exploratory character of newly proposed
molecular CRC classification systems, validation stud-
ies in external patient cohorts are essential before the
usefulness of the proposed classification can be
judged. In this large cohort study, we were able to
perform validation of three previously proposed classi-
fication systems by incorporating the same set of mo-
lecular markers. We attempted to imitate the original
analyses by adjusting for the same set of confounders
in each case; however, there might still be differences
in the assessment and definition of the variables lead-
ing to differences in the calculated estimates. On the
other hand, not all hitherto proposed classifications
could be validated in our study [14], since not all in-
formation required to construct the molecular sub-
types was available. Also, although it is a large study,
sample size decreases when stratifying patients into
several subtypes and restricting the populations to
match the ones reported by the original studies,
which limits the power for the statistical analyses. Fi-
nally, the time periods when the patients were re-
cruited span different decades and this could mean
the chemotherapy regimens used were different be-
tween the studies.
Conclusions
In conclusion, the results of this validation analysis con-
tribute to the evolving interest in the development of an
extended clinically meaningful classification for CRC.
None of the published classifications has so far provided
a definitive subtyping that allows to predict patient sur-
vival in all groups. Our results support the conclusion
that MSS subtypes including BRAF or KRAS mutations
have a worse prognosis compared to those without the
latter mutations and that those subtypes can be readily
generalized to most other patient populations. The role
of CIMP status was less clear in the prediction of sur-
vival, and it is known to be highly associated with MSI.
Our extended analysis supported that the observed asso-
ciations were similar in patient subgroups that were not
included in the original studies. However, as for the MSI
subtypes, where other characteristics such as stage, loca-
tion and sex are highly correlated, may require more
careful evaluation before generalizing their potential sur-
vival benefit. Also, further information from methylation,
gene expression, and immune response analyses in
tumor tissue may help to further improve the definition
of clinically relevant molecular subtypes. The present
knowledge about molecular subtypes of colorectal can-
cer suggests that the stage of disease remains the most
important predictor of survival, and that more research
is needed to find molecular tumor markers or combina-
tions that help to complement this system.
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